 ?您的位置：對(duì)照品 > 標(biāo)準(zhǔn)品 > 歐洲藥典標(biāo)準(zhǔn)品 > |
|
|
|
| 產(chǎn)品基本信息 |
|
| 產(chǎn)品編號(hào)：M199803 |
| 產(chǎn)品名稱：MDV 3100-d6 (Enzalutamide-d6) |
| 產(chǎn)品CAS：1443331-94-9 |
| 規(guī)格含量：2.5mg |
| 產(chǎn)品價(jià)格：面議 |
| 聯(lián)系我們: |
 |
|
 |
|
|
| 產(chǎn)品詳細(xì)介紹 |
| 標(biāo)準(zhǔn)品編號(hào): |
M199803 |
| 名稱: |
MDV 3100-d6 (Enzalutamide-d6) |
| 別名: |
4-[3-[4-Cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl]-2-fluoro-N-methylbenzamide-d6; MDV3100-d6; |
| CAS號(hào): |
1443331-94-9 |
| 參考CAS號(hào): |
類似: 915087-33-1 |
| 分子式: |
C??H??D?F?N?O?S |
| 分子量: |
470.47 |
| 種類: |
Standards; Isotopic Labeled Analogues; Pharmaceutical/API Drug Impurities/Metabolites; |
| 應(yīng)用: |
Isotope labelled MDV 3100 is an androgen-receptor antagonist that blocks androgens from binding to the androgen receptor and prevents nuclear translocation and co-activator recruitment of the ligand-receptor complex. MDV 3100 has also been shown to induce tumor cell apoptosis, and has no agonist activity. MDV 3100 is a candidate for the treatment of castration-resistant prostate cancer. |
| 參考文獻(xiàn) |
|
|
|
|
|
|
